Inicio>>Signaling Pathways>> Membrane Transporter/Ion Channel>> TRP Channel>>SB 366791

SB 366791

Catalog No.GC14997

SB 366791 es un potente y selectivo antagonista del receptor vaniloide (VR1/TRPV1) (IC50\u003d5,7 nM).

Products are for research use only. Not for human use. We do not sell to patients.

SB 366791 Chemical Structure

Cas No.: 472981-92-3

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO) Please Inquire Please Inquire
10mg
65,00 $
Disponible
50mg
222,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

SB-366791 is a potent , competitive and selective vanilloid receptor (VR1/TRPV1) antagonist with IC50 of 5.7±1.2 nMtarget: VR1/TRPV1IC 50: 5.7±1.2 nM [1] SB-366791 produced a concentration-dependent inhibition of the response to capsaicin with an apparent pKb of 7.74±0.08. Schild analysis indicated a competitive mechanism of action with a pA2 of 7.71.[1] SB-366791 showed a concentration-dependent potentiation of pH 5-induced 45Ca2+uptake in CHO cells expressing rat TRPV1 but not in untransfected cells[2]

References:
[1]. M.J. Gunthorpe et al. Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist. Neuropharmacology, 2004 Jan, 46(1):133-49.
[2]. Gavva NR et al. Proton Activation Does Not Alter Antagonist Interaction with the Capsaicin-Binding Pocket of TRPV1. Mol Pharmacol, 2005 Dec, 68(6), 1524-33.

Reseñas

Review for SB 366791

Average Rating: 5 ★★★★★ (Based on Reviews and 24 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SB 366791

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.